ORGANIZATION
Experts Talk over Biosimilar Challenges, Chide Unstable Supplies and Indication Gaps
July 19, 2019
While Japan has witnessed rapid generic inroads over the past years on the back of active government promotions, biosimilars are not making the same headway, with different levels of penetration seen in different markets. What…

LATEST

July 19, 2019
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) demonstrated a hefty 78% reduction in the risk of deaths when used in a first-line setting in Japanese patients with relapsed/metastatic head and neck cancer whose tumors have a high…
July 19, 2019
Daiichi Sankyo’s peripheral neuropathic pain treatment Tarlige (mirogabalin) was the most promoted drug in the month of April, with its sales reps stepping up their calls as the product hit the market in middle of the month, an industry survey…
July 19, 2019
The Japan Pancreas Society has published the 2019 guidelines for the treatment of pancreatic cancer, the first revision in three years, recommending FOLFIRINOX therapy and the gemcitabine and nab-paclitaxel (nab-PTX) combination as first-line chemotherapies for locally advanced or metastatic unresectable…
By Reiji Anasako

Despite getting off to a sluggish start five years ago, SGLT2 inhibitors are steadily picking up steam thanks to buoyant sales of their combination medicines with DPP-4 inhibitors. Even monodrugs alone grew 29% in FY2018, with the market including the…

By Tatsuya Otsuka

Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…

By Yoshinori Sagehashi

With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Yoshinori Sagehashi

As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA